# FS-1 Drug for Treatment of Multiple Drug-resistant Tuberculosis

> **NCT02607449** · PHASE3 · COMPLETED · sponsor: **Scientific Center for Anti-infectious Drugs, Kazakhstan** · enrollment: 344 (actual)

## Conditions studied

- Tuberculosis, MDR

## Interventions

- **DRUG:** FS-1
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02607449
- **Lead sponsor:** Scientific Center for Anti-infectious Drugs, Kazakhstan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2020-08
- **Final completion:** 2020-10
- **Target enrollment:** 344 (ACTUAL)
- **Last updated:** 2022-05-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02607449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02607449, "FS-1 Drug for Treatment of Multiple Drug-resistant Tuberculosis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02607449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*